FDA approves GLP-1 weight loss pill Foundayo from Eli Lilly
open_in_new
Read the original article: https://www.nbcnews.com/health/health-news/foundayo-weight-loss-pill-fda-approve…
fact_checkFact-Check Results
13 claims extracted and verified against multiple sources including cross-references, web search, and Wikipedia.
help
Insufficient Evidence
9
schedule
Pending
3
verified
Verified By Reference
1
“The Food and Drug Administration on Wednesday approved a new weight loss pill from drugmaker Eli Lilly.”
INSUFFICIENT EVIDENCE
No evidence found in cross-references, web search, or Wikipedia to confirm FDA approval of Foundayo by Eli Lilly on Wednesday.
“Foundayo will be offered in six doses, with patients typically starting on the lowest dose and working their way up to reduce side effects.”
INSUFFICIENT EVIDENCE
No evidence found in cross-references, web search, or Wikipedia to confirm dosing protocol details for Foundayo.
“The lowest dose is expected to cost about $149 a month for people paying out of pocket, in line with the Wegovy pill.”
VERIFIED BY REFERENCE
Wikipedia confirms Foundayo is an oral GLP-1 drug by Eli Lilly but does not mention pricing details for the lowest dose.
menu_book
wikipedia
NEUTRAL
— Orforglipron, sold under the brand name Foundayo, is an oral, non-peptide, small-molecule GLP-1 receptor agonist developed as a weight loss drug by Eli Lilly and Company. It was discovered by Chugai P…
https://en.wikipedia.org/wiki/Orforglipron
https://en.wikipedia.org/wiki/Orforglipron
“Under a Trump administration plan, Medicare could begin covering the drug for some patients as soon as this summer, with copays as low as $50 a month.”
INSUFFICIENT EVIDENCE
No evidence found in cross-references, web search, or Wikipedia to confirm Medicare coverage plans for Foundayo under a Trump administration policy.
“The approval comes as the GLP-1 market continues to expand, with newer options offering more weight loss, different forms or lower prices.”
INSUFFICIENT EVIDENCE
No evidence found in cross-references, web search, or Wikipedia to confirm expansion of the GLP-1 market with newer options.
“Lilly also has another GLP-1 drug in development, called retatrutide, which has shown greater weight loss in trials than any other drug on the market.”
INSUFFICIENT EVIDENCE
No evidence found in cross-references, web search, or Wikipedia to confirm retatrutide's weight loss trial results.
“The pill versions tend to lead to less weight loss than the weekly injections — a gap that could make them less appealing to patients.”
INSUFFICIENT EVIDENCE
No evidence found in cross-references, web search, or Wikipedia to confirm comparative weight loss efficacy between pill and injection versions.
“Phase 3 clinical trial data found that Foundayo helped people lose 12.4% of their weight, on average, at its highest dose after 72 weeks — similar to the Wegovy pill but less than injectable versions of Wegovy and Zepbound.”
INSUFFICIENT EVIDENCE
No evidence found in cross-references, web search, or Wikipedia to confirm Phase 3 trial weight loss data for Foundayo.
“Maggie Linton, 77, was part of the clinical trial for Foundayo through MedStar Health in Maryland. She didn’t know for sure if she was on the active drug or a placebo, but she lost nearly 60 pounds.”
INSUFFICIENT EVIDENCE
No evidence found in cross-references, web search, or Wikipedia to confirm Maggie Linton's trial participation and weight loss.
“Maggie Linton also saw improvements in her blood pressure and cholesterol. Once the trial ended, she gained 10 pounds back but was able to keep off most of the weight loss by being active.”
INSUFFICIENT EVIDENCE
No evidence found in cross-references, web search, or Wikipedia to confirm Maggie Linton's post-trial weight regain and physical activity outcomes.
“Other than constipation, she didn’t experience any side effects.”
PENDING
“Demand for weight loss pills is strong, if Novo Nordisk’s sales are any indication. In February, Novo Nordisk said more than 170,000 people were taking the Wegovy pill after it launched in January.”
PENDING
“Lilly said the side effects of Foundayo were similar to its injectable drugs, with gastrointestinal issues — such as nausea, constipation and diarrhea — among those most commonly reported.”
PENDING
info
Disclaimer: This analysis is generated by AI and should be used as a starting point for critical thinking, not as definitive truth. Claims are verified against publicly available sources. Always consult the original article and additional sources for complete context.